- Spark Newswire

4 minute read

Portage Biotech Acquires Tarus Therapeutics In Exchange For 2,425,999 PRTG Shares Along With Assumption Of $3M In Liabilities; Additionally, Payments Of Up To $32M Would Be Triggered Upon Achievement Of Future Milestones

Yesterday, 4:13 PM

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at

PRTG

1 minute read

Saratoga Investment Q1 EPS $0.53, Inline

By Bill Haddad

Yesterday, 4:08 PM

Saratoga Investment (NYSE:SAR) reported quarterly earnings of $0.53 per share which met the analyst consensus estimate. This is a 5.36 percent decrease over earnings of $0.56 per share from the same period last year.

SAR

1 minute read

Simulations Plus Q3 EPS $0.20 Beats $0.17 Estimate, Sales $15.00M Beat $14.33M Estimate

By Bill Haddad

Yesterday, 4:06 PM

Simulations Plus (NASDAQ:SLP) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 11.11 percent increase over earnings of $0.18 per share from the

SLP

2 minute read

Calithera Biosciences Announces First Patient Enrolled In Phase 2 Clinical Trial Of Sapanisertib In Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

By Bill Haddad

Yesterday, 4:01 PM

Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in

CALA